Antibiotics discs used in the experiment included Ticarcillin (70ug), Cefixime (5ug), Cloxacillin (1ug), Sulphaphenazol (200ug), Gentamicine (10ug), Amoxicillin (30ug),Vancomycin (30ug), Ceftaxime (30ug), Ceftazidine (30ug), Amoxicillin (25ug), Cefuroxime (30ug), Ciprofloxacillin (5ug), Ampicillin (10ug), Oxacillin (1ug), Amicacin (30ug), Azlocillin (75ug), Piperacillin Tazabactam (100:10 ug), Ticarcillin Calvanic acid (75:10ug), Triple Sulphas (300ug), Cinoxacin (100ug), Mupiracin (5ug), Spectinomycin (100ug), Chloramphenicol (25ug), Trimethoprim (30ug).
aureus to other antibiotics included Sulphaphenazol (93%), Gentamicin (93%), Cefotaxime (84%), Triple sulpha, Amikacin (77%), Cinoxacin (55%), and Piperacillin Tazabactam combination (54%).
1996) found 72% isolates sensitive to cinoxacin
which is congruent to this study.
This is supported by the study of Turner et al28 who reported that single amino acid substitutions in GyrA was sufficient for resistance to the quinolones nalidixic acid and cinoxacin
, but resistance to the fluoroquinolones (gatifloxacin, ofloxacin, ciprofloxacin, enrofloxacin and moxifloxacin) required two substitutions in GyrA and one in ParC.
Cross-resistance among cinoxacin
, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
2005) reported that cinoxacin
(antibiotic) had remarkable effect on the cellular and sub- cellular structure of Chlorella sp.
Urinary germicides include cinoxacin
(Cinobac) [C], methenamine [C], nalidixic acid (NegGram) [C], and nitrofurantoin (Macrodantin) [B].
Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin
by high performance liquid chromatography: application to levofloxacin determination in human plasma.
Fiscal year sales and earnings were also boosted by sales of other new products approved during the 1992 calender year, including cinoxacin
, baclofen, minocycline and metaproterenol syrup.
(Cinobac) is rated category B, but there are no fetal risk or breast-feeding data on this drug.
They included the first FDA approvals for cinoxacin
(a generic oral quinolone) and minocycline, which is the generic equivalent of Lederle Laboratories' Minocin.